New therapy data, scientific findings and practical reports on indwelling pleural or peritoneal catheter (IPC) therapy.
Pleural effusion and ascites are a considerable burden for many patients and require targeted, patient-friendly therapy. The IPC has established itself as an effective option, but what factors influence the success of the therapy? What new scientific findings are there on cost-effectiveness and infection management? And how does the use of an IPC affect patients’ quality of life?
The ewimed Report 2025 provides well-founded answers. Based on the current 2024 data collection of the ewimed patient questionnaire, which has been collected throughout Germany for 15 years, the report analyses treatment data and clinical developments. Supplemented by a current scientific study on the cost-effectiveness of IPC implantations, expert opinions and practical case studies, it offers valuable insights for doctors, medical professionals and clinics.
The following topics are included for you:
Treatment data 2024: Analysis of the ewimed patient questionnaire on implantation figures, indications and treatment decisions.
Literature update: Analysis of a current study on resource utilisation and the costs of IPC implantations compared to pleurodesis.
Infections in non-malignant ascites: Presentation of a new study on silver-containing IPCs that demonstrates a significant reduction in the risk of infection - including an interview with Prof Dr Benjamin Maasoumy from Hannover Medical School.
Sustainability in the healthcare sector: International insights into the implementation of sustainable measures in European clinics as well as an expert exchange with PD Dr Stefan Welter (Lungenklinik Hemer) and Martina Moll (Sana Kliniken AG).
